Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Company enters 2026 focused on disciplined expansion, national partnerships, and scalable solutions to the growing ...
FLYING Magazine on MSN
Joby Acquires New Facilities and Simulators as Air Taxi Launch Looms
Joby says a new 700,000-square-foot production facility in Dayton, Ohio, will enable production of four air taxis per month ...
Atlanta seems ready to move on from the Trae Young era. Which teams make realistic trade partners — and which ones don't?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback